$1.19
4.39% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US91381U1016
Symbol
UBX
Sector
Industry

Unity Biotechnology, Inc. Stock price

$1.19
-0.15 11.19% 1M
-0.29 19.59% 6M
-0.74 38.34% YTD
-0.73 38.02% 1Y
-22.01 94.87% 3Y
-67.81 98.28% 5Y
-165.31 99.29% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.05 4.39%
ISIN
US91381U1016
Symbol
UBX
Sector
Industry

Key metrics

Market capitalization $20.05m
Enterprise Value $15.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.42
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-32.76m
Free Cash Flow (TTM) Free Cash Flow $-22.54m
Cash position $29.04m
EPS (TTM) EPS $-1.32
P/E forward negative
Short interest 1.82%
Show more

Is Unity Biotechnology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Unity Biotechnology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Unity Biotechnology, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Unity Biotechnology, Inc. forecast:

Buy
100%

Financial data from Unity Biotechnology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.90 0.90
34% 34%
-
-0.90 -0.90
34% 34%
-
- Selling and Administrative Expenses 16 16
1% 1%
-
- Research and Development Expense 15 15
34% 34%
-
-32 -32
21% 21%
-
- Depreciation and Amortization 0.90 0.90
34% 34%
-
EBIT (Operating Income) EBIT -33 -33
21% 21%
-
Net Profit -22 -22
58% 58%
-

In millions USD.

Don't miss a Thing! We will send you all news about Unity Biotechnology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Unity Biotechnology, Inc. Stock News

Neutral
GlobeNewsWire
22 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024.
Neutral
GlobeNewsWire
4 months ago
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024.
Neutral
GlobeNewsWire
4 months ago
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies.

Company Profile

Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi and Daohong Zhou on March 30, 2009 and is headquartered in Brisbane, CA.

Head office United States
CEO Anirvan Ghosh
Employees 19
Founded 2009
Website www.unitybiotechnology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today